A commercial transition rewritten by an acquisition agreement
- Lantheus signed a definitive merger agreement on August 3, 2026, to be acquired by Curium.
- The primary investment story has shifted from standalone execution to the successful closing of this transaction.
- PYLARIFY remains the center of the portfolio, generating $240.9 million in Q1 2026 Oncology revenue.
- The FDA issued a Complete Response Letter for LNTH-2501 in June 2026 over facility inspection issues.
- If the merger fails, Lantheus faces a potential termination fee of $228.0 million.
The standalone story ends with a buyout
The investment thesis for Lantheus shifted dramatically on August 3, 2026. The company signed a definitive agreement to be acquired by Curium US Holdings LLC. This move takes a complex 2027 commercial transition and replaces it with a simple M&A closing process.
The bull case is straightforward. The merger closes successfully, delivering an agreed premium to shareholders. This eliminates the operational risks of the planned PYLARIFY TRUVU transition and any lingering pipeline setbacks, such as the recent FDA delay for LNTH-2501.
The bear case centers on the deal breaking. If antitrust regulators block the merger or other closing conditions fail, Lantheus would be forced back to a standalone footing. In that scenario, the company might owe a $228.0 million termination fee. It would then have to navigate its crucial commercial transitions under the cloud of a broken deal and potential employee turnover.
Selling short-lived medical tracers
Lantheus makes money by selling diagnostic agents to radiopharmacies, hospitals, and clinics. These agents are used with imaging machines so doctors can see disease inside the body. PET means positron emission tomography, a scan that uses a small radioactive tracer.
The company had narrowed its focus entirely toward PET radiodiagnostics. It sold its legacy SPECT business in January 2026 and began looking for alternatives for its radiotherapeutic pipeline.
With the August 2026 merger agreement, the long-term independent business model will soon change. If the deal closes, Lantheus will become a wholly-owned subsidiary of Curium and integrate into its broader radiopharmaceutical network.
Four pillars and two options
PYLARIFY
PYLARIFY is the market-leading PSMA-targeted PET imaging agent for prostate cancer. It is the primary revenue driver.
PYLARIFY TRUVU
TRUVU is the newly approved PYLARIFY formulation. Its main promise is better manufacturing output, with a commercial transition planned to start in Q4 2026.
NEURACEQ
NEURACEQ is a PET imaging agent used to show beta-amyloid plaque in Alzheimer's disease. It produced $35.4 million in Q1 2026 revenue.
DEFINITY
DEFINITY is an ultrasound-enhancing agent used in cardiology. It gives Lantheus a steady base outside oncology.
MK-6240
MK-6240 is a tau-targeted PET diagnostic for Alzheimer's disease. Its FDA action date is August 13, 2026.
LNTH-2501
LNTH-2501 is an imaging agent that received a Complete Response Letter from the FDA in June 2026 over third-party manufacturing issues.
PYLARIFY still dominates sales
This mix is from Q1 2026, after Lantheus reconfigured reporting. Oncology was about 63.8% of total revenue, showing how critical PYLARIFY remains.
What could break the setup
Merger termination and antitrust blocks
High impact · Medium oddsThe primary risk is the pending merger with Curium failing to close. If antitrust hurdles or other conditions block the deal, Lantheus could owe a $228.0 million termination fee. It would also face the difficulty of returning to standalone operations.
TRUVU site-by-site launch friction
Medium impact · Medium oddsIf the merger breaks, Lantheus still has to move customers and radiopharmacies over to PYLARIFY TRUVU in Q4 2026. If sites are not ready, revenue could be disrupted during the handoff.
LNTH-2501 manufacturing delay
Low impact · High oddsThe FDA issued a Complete Response Letter for LNTH-2501 in June 2026. The issue was tied to unresolved manufacturing conditions at a third-party facility. While eclipsed by the merger, it remains an operational delay.
Operational restrictions during pendency
Medium impact · Medium oddsWhile waiting for the merger to close, Lantheus faces standard operational restrictions. These can slow down strategic decisions, hiring, and new partnerships.
In one breath
What does Lantheus do?
Lantheus sells medical imaging agents. These products help doctors see prostate cancer, heart function, and signs of Alzheimer's disease using PET scans or ultrasound.
Why is the company being acquired?
On August 3, 2026, Lantheus agreed to merge with Curium US Holdings LLC. This move secures a premium for shareholders and removes the risk of executing future commercial transitions alone.
What happened to LNTH-2501?
The FDA issued a Complete Response Letter in June 2026. The problem was tied to manufacturing conditions at a third-party facility, not a stated concern about safety or efficacy.
Is Lantheus only a cancer imaging company?
No. Oncology is the largest segment, but Lantheus also has Cardiology through DEFINITY and Neurology through NEURACEQ.
